Skip to main content
Clinical Trials/EUCTR2014-002539-32-NO
EUCTR2014-002539-32-NO
Active, not recruiting
Phase 1

The WE Study - Walking Easier with cerebral palsy

St. Olavs University Hospital0 sites96 target enrollmentDecember 3, 2014

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
cerebral palsy
Sponsor
St. Olavs University Hospital
Enrollment
96
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 3, 2014
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
St. Olavs University Hospital

Eligibility Criteria

Inclusion Criteria

  • Eligible to participate in the study are children and adolescents with spastic cerebral palsy referred to the out\-patient clinics at the participating sites and regional partners, for injection of BoNT\-A in the calf muscles.
  • All of the following conditions must apply to the prospective patient at screening prior to receiving study agent (e.g.):
  • Diagnosed with unilateral or bilateral CP in their medical record
  • GMFCS level I and II
  • Must be at least 4 years of age.
  • Spasticity in the calf muscles, clinically judged as grade 2 or 3 (the presence of a spastic catch) according to the Tardieu Scale.
  • Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 96
  • F.1\.2 Adults (18\-64 years) no

Exclusion Criteria

  • Patients will be excluded from the study if they meet any of the following criteria:
  • BoNT\-A injections in the lower limbs in the last 6 months before intervention
  • History of adverse reactions to BoNT\-A
  • Known hypersensitivity to BoNT\-A or to any of the excipients
  • Orthopedic surgery in the lower limbs in the last 2 years
  • Major cognitive impairments (must be able to take verbal instructions and conduct the test procedure)
  • Presence of infection at the proposed injection site(s)
  • Subclinical or clinical evidence of defective neuromuscular transmission e.g. myasthenia gravis or Lambert\-Eaton Syndrome in patients with peripheral motor neuropathic diseases (e.g. amyotrophic lateral sclerosis or motor neuropathy) or other underlying neurological disorders that may be affected by BoNT\-A injections
  • Pregnant or breast\-feeding
  • Childbearing potential not using contraception

Outcomes

Primary Outcomes

Not specified

Similar Trials